KOLs in breast cancer provide insights on de-escalation of adjuvant antiHER2 therapy and need for HER2 testing of residual disease after neoadjuvant therapy.
Website: [ Ссылка ]
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
LinkedIn: [ Ссылка ]
![](https://i.ytimg.com/vi/ALAqxFuZEUs/mqdefault.jpg)
KOLs in breast cancer provide insights on de-escalation of adjuvant antiHER2 therapy and need for HER2 testing of residual disease after neoadjuvant therapy.
Website: [ Ссылка ]
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
LinkedIn: [ Ссылка ]